Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GS-6615 for reducing ventricular arrhythmia events in patients with ICD or CRT-D
2013-004430-15Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ventricular arrhythmia (VA) comparing GS-6615 dose-ranging arm(s) with Placebo (2 arms). Primary endpoint: Overall occurrence of appropriate ICD interventions through Week 24. Started Aug 2014; status: completed.
02
Drugs
eleclazine
03
Conditions
ventricular arrhythmia (VA)
Beyond the preview
Go deeper on 2013-004430-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004430-15.